

November 30, 2021

National Stock Exchange of India Ltd Listing Department Exchange Plaza, 5th Floor, Plot No: C/1, G - Block, Bandra- Kurla Complex, Bandra (East), Mumbai - 400 051 NSE Symbol: ORCHPHARMA	BSE Limited Corporate Relationship Department 1st floor, New Trading Ring, Rotunda Building, P J Towers, Dalal Street, Fort Mumbai - 400 001 BSE Code: 524372
--	--

Dear Sir/Madam

Subject: Disclosure under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the disclosure on Related Party Transactions, on a consolidated basis, prepared in accordance with the applicable accounting standards for the half year ended September 30, 2021.

This disclosure will also be made available on the website of the Company and can be accessed using the link http://www.orchidpharma.com/invr_intimation.aspx

Kindly take the above information on records.

Thanking you,
Yours faithfully,

For **Orchid Pharma Limited**

Sunil Kumar Gupta
Chief Financial Officer



Enclosures: A/a

CONSOLIDATED DISCLOSURE OF RELATED PARTY TRANSACTION & BALANCES FOR THE HALF
YEAR ENDED SEPTEMBER 30, 2021



I. Related parties and their relationship:

A) Holding company

- i. Dhanuka Laboratories Limited

B) Subsidiary Companies

- i. Orchid Europe Limited, UK
- ii. Orchid Pharmaceuticals Inc., USA
- iii. Orchid Pharmaceuticals SA (Proprietary) Limited, South Africa
- iv. Bexel Pharmaceuticals Inc. USA
- v. Diakron Pharmaceuticals Inc., USA
- vi. Orgenus Pharma Inc., USA (Subsidiary of Orchid Pharmaceuticals Inc USA.)
- vii. Orchid Pharma Inc / Karalex Pharma USA (Subsidiary of Orchid Pharmaceuticals Inc, USA)

C) Associate Company

- i. OrBion Pharmaceuticals Private Limited

D) Directors & Key Management Personnel

- i. Mr. Ram Gopal Agarwal, Chairman and Non-Executive director
- ii. Mr. Manish Dhanuka, Managing Director
- iii. Mr. Mridul Dhanuka, Whole time Director
- iv. Mr. Arun Kumar Dhanuka, Non-Executive Director
- v. Dr. Dharam Vir, Independent Non-Executive Director
- vi. Mr. Manoj Kumar Goyal, Independent Non-Executive Director
- vii. Mr. Mudit Tandon, Independent Non-Executive Director
- viii. Ms. Tanu Singla, Independent Non-Executive Director
- ix. Mr. Sunil Kumar Gupta, Chief Financial Officer
- x. Ms. Nikita K, Company Secretary

D) Entities controlled by KMP/relative of KMP, with whom transactions have taken place

- i. Synmedic Laboratories

Manish Dhanuka



S. K. Singh



E) Other related parties with whom transactions have taken place

- i. Otsuka Chemicals (India) Private Limited (As per Section 2(76) (iv) of the Companies Act,2013)

II. The following transactions were carried out with the related parties during the period April 01, 2021 to September 30, 2021 in the Ordinary course of business and at arm's length basis

Name of the Related Party	Nature of Relationship	Nature of Transactions	Value (Amount in INR Lakhs)
Dhanuka Laboratories Limited	Holding Company	Purchase of goods	823.56
		Sale of goods	772.24
Orchid Pharma Inc	Subsidiary Company	Sale of goods	734.34
Otsuka Chemical (India) Private Limited	Related party as per Section 2(76) (iv) of the Companies Act,2013	Purchase of goods	3660.46

Compensation to Key Management Personnel			
Transaction	Type of relation	Amount (Rs. In Lakhs)	Balance Outstanding Dr. / (Cr.)
Short term employee benefits	Key Management Personnel (Managing Director, Whole Time Director and Company Secretary) #	75.75	13.17
Sitting fee to Non-Executive Directors	Mr. Ram Gopal Agarwal, Chairman & Non-Executive Director Mr. Arun Kumar Dhanuka, Non-Executive Director Dr Dharam Vir, Independent Director Mr. Manoj Kumar Goyal, Independent Director Mr. Mudit Tandon, Independent Director Ms.TanuSingla, Independent Director	4.35	-
# No remuneration was paid to Mr. Sunil Kumar Gupta, Chief Financial Officer during the period April 01,2021-September 30,2021			

M. Dhanuka



S.K.S.117



Balances with related Parties as on September 30, 2021:

Name of the Related Party	Nature of Relationship	Nature of Transactions	Outstanding Balances (Amount in INR Lakhs)
Dhanuka Laboratories Limited	Holding Company	Trade payable	6.23
		Trade receivables	772.33
Orchid Europe Limited, UK	Subsidiary Company	Trade payable	31.12
Orchid Pharma Inc	Subsidiary Company	Trade receivables	4148.26
Synmedic Laboratories	Entities controlled by KMP/relative of KMP	Trade receivables	-
Otsuka Chemical (India) Private Limited	Related party as per Section 2(76) (iv) of the Companies Act, 2013	Trade payable	-

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year-end are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. A provision has been created for invoices raised from financial year 2017-2018 till date. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

For Orchid Pharma Limited

Manish Dhanuka
Managing Director



For Orchid Pharma Limited

Sunil Kumar Gupta
Chief Financial Officer